We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

Principia is a late-stage biopharmaceutical company dedicated to bringing transformative therapies to patients with significant unmet medical needs in immune-mediated diseases. Through Principia’s proprietary Tailored Covalency® platform, our strategy is to build and advance a pipeline of best-in-class drug candidates with significant therapeutic benefits, limit unintended side effects, improve quality of life and over time modify the course of disease. Rilzabrutinib, a reversible covalent BTK inhibitor, is being evaluated in a global Phase 3 clinical trial in patients with pemphigus, a Phase 1/2 clinical trial in patients with immune thrombocytopenia (ITP), and the company plans to initiate a Phase 2 clinical trial in patients with IgG4-Related Diseases.

SOUTH SAN FRANCISCO, Calif., March 10, 2020 -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for.

Principia Biopharma stock has rocketed 32% this week amid enthusiasm for its technology, BTK inhibition — highlighted by notable moves from pharmaceutical giants Merck and Sanofi.

SOUTH SAN FRANCISCO, Calif., May 06, 2020 -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for.

SOUTH SAN FRANCISCO, Calif., May 26, 2020 -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for.

(Bloomberg Opinion) -- Eddie Yoon took over the Fidelity Select Health Care Fund in 2008, just as the financial crisis ushered in the worst recession since the Great Depression. He outperformed health-care's benchmark during the ensuing 12 years when his fund quintupled to almost $7 billion. That record made him No. 1 among 20 peers managing at least $200 million with combined 1-to-5-year returns, according to data compiled by Bloomberg.He has never seen anything like the Covid-19 pandemic, an unprecedented disruption that, for the first time, he says, is aligning patients, health-care providers and payers, including insurers.The coronavirus has “fundamentally changed the way we think about the outlook,” said the 40-year-old Yoon earlier this month in a remotely arranged interview near Fidelity's Boston headquarters. “Big winners and losers are going to emerge, and that provides an enormous opportunity for folks like us that run active funds that really capitalize on the companies that are going to be successful in that new world.”Basel-based Roche Holding AG, Indianapolis-based Eli Lilly & Co., London-based AstraZeneca PLC and South San Francisco-based Principia Biopharma Inc. are “still are very big parts” of Fidelity Select Health Care. They appreciated 20%, 17%, 14% and 110%, respectively, during the past 12 months.Yoon said he relies on the “same investment framework that we've been using for over 10 years.” This means focusing simultaneously on free cash flow — how much money a business has to sustain its operations after paying for buildings, equipment and other capital expenditures — and the long-term growth rates of companies.“We construct a portfolio where we're trying to extract the most amount of return — income plus appreciation — for the least amount of risk,” Yoon said. “With the demand shock we're seeing in our economy as well as this public health-care crisis, things are changing rapidly, so when you are uncertain, you want more downside protection or more upside opportunity.”Fidelity Select Health Care almost tripled its weighting in Western European companies compared with the MSCI US Health Care Index during the past three years at the expense of U.S. companies whose underweighting increased to 19% from 10% versus the benchmark, according to data compiled by Bloomberg. “Coming into 2019, we were de-risking” as “a lot of growth stocks got very, very expensive,” said Yoon, who joined Fidelity after an initial stint at JPMorgan Asset Management starting in 2002, when he received a B.A. in business economics from Brown University.  “We actually narrowed the pharmaceuticals positioning in the fund, and I own more large pharma companies now than I have before.”Fidelity Select Health Care gained 9.3% during the past 12 months, outperforming the benchmark by 5.2% when the MSCI declined 4.1%. Most of the return came from the pharmaceutical companies he selected even when the fund held fewer of them than the benchmark, according to data compiled by Bloomberg.“My general philosophy is deliver a double-digit return for shareholders that will outperform the underlying benchmark and other asset classes that investors might want to put their capital into,” Yoon said. The fund returned 549% since he became its manager. Health care remains something of a haven during periods of market turbulence. When the S&P 500 index lost 12% last month, the shares of health-care companies lost only 3.8% when the comparable measures for the financial and energy industries declined 21% and 35%, respectively. During the last recession, between December 2007 and June 2009, health care retreated 25% when the S&P 500 decreased 35%, according to data compiled by Bloomberg.Yoon, who also oversees Fidelity's global health-care research, said “until we get to a way to find a health-care breakthrough — whether it be a therapeutic, a preventative medicine, helping people develop antibodies against the coronavirus or a vaccine — we're going to have to deal with this coronavirus as we think about the demand picture for the foreseeable future.”While Yoon dealt with the upheaval of the financial crisis in 2008 and 2009 and the disruption caused by the 2010 Affordable Care Act, which went into effect in 2013, “this time it's different,” he said.“The companies that we're trying to find that actually are impacted by this crisis are companies that are going to see a cyclical benefit where demand is going to rise because of the coronavirus and then stay high for longer because of something unique in their business model. Those are the companies we own and will hopefully own for a long time.”\-- With assistance from Shin Pei, Cara Slear and Chase Lynch.This column does not necessarily reflect the opinion of Bloomberg LP and its owners.Matthew A. Winkler is Co-founder of Bloomberg News (1990) and Editor-in-Chief Emeritus; Bloomberg Opinion Columnist since 2015; Co-founder of Bloomberg Business Journalism Diversity Program in 2017. During his 25 years as Editor-in-Chief, Bloomberg News was a three-time finalist and winner of the Pulitzer Prize for Explanatory Reporting and received numerous George Polk, Gerald Loeb, Overseas Press Club and Society of Professional Journalists and Editors (Sabew) awards.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced that management will participate in the Stifel Healthcare Conference on Tuesday, November 19, 2019, at 11:30 am EST in the Garrison Room at the Lotte New York Palace Hotel. Principia is a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases.

As lawmakers talk about drug price controls, drug developers are simply trying to find a place to stay during the J.P. Morgan Healthcare Conference for under $1,000 a night.

Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced that management will participate in the SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020, at 10:00 am EST at the Lotte New York Palace Hotel. Principia is a late-stage biopharmaceutical company dedicated to bringing transformative therapies to patients with significant unmet medical needs in immune-mediated diseases. Rilzabrutinib, a reversible covalent BTK inhibitor, is being evaluated in a Phase 3 clinical trial in patients with pemphigus -- an orphan autoimmune disease -- a Phase 2 clinical trial in patients with immune thrombocytopenia (ITP), and the company plans to initiate a Phase 2 clinical trial in patients with IgG4-related diseases.

Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, today announced an expansion in the development of rilzabrutinib (PRN1008) into IgG4-Related Disease (RD). This clinical program broadens the company’s Bruton tyrosine kinase (BTK) therapeutic areas and supports the company’s commitment to innovate and solve high unmet needs.

Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced consistent positive data from an ongoing Phase 1/2 trial of its investigational treatment, PRN1008, in 31 highly treatment-resistant and refractory patients (median of six prior therapies) with immune thrombocytopenia (ITP). The data from the trial is being presented today by David Kuter, M.D., Director of Clinical Hematology at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School, at an oral scientific session of the 61st American Society of Hematology Annual Meeting (ASH).

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2019 -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune.

Company expands focus on immune-mediated diseases and suspends FGFR program Company outlines anticipated key corporate milestones SOUTH SAN FRANCISCO, Calif.,.

Principia Biopharma Inc. (PRNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...

Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immune-mediated diseases, today announced updated anticipated timing for final results in its ongoing pivotal Phase 3 clinical trial of PRN1008 data in patients with pemphigus, as well as complete response rates from its Phase 2 Part B open-label trial.

Principia Biopharma Inc. (PRNB) delivered earnings and revenue surprises of -9.41% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Principia Biopharma Inc. (PRNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.